PGLA

Progen Receives NASDAQ Deficiency Notice - 09/08 - 06:38 AM ET

Progen drops main product - 07/23 - 04:52 PM ET

Progen Pharmaceuticals Plunges On Discontinuing Liver Cancer Study - 07/23 - 04:27 PM ET

Progen terminates Phase III liver cancer trial - 07/23 - 10:53 AM ET

PGLA: Terminates Phase 3 Trial of PI-88 in Liver Cancer - 07/23 - 08:15 AM ET

Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A - 07/22 - 08:35 PM ET

Diverse talents in young executive field - 07/10 - 04:54 PM ET

Presentation of Data on Progen's Cancer Epigenetic Targets Platform - 05/30 - 01:52 AM ET

Progen resumes Phase I cancer trial - 05/15 - 09:58 AM ET

PGLA: Resumes Patient Enrollment for Ph I Trial of PG-11047 for Advanced Cancer - 05/15 - 09:33 AM ET

Progen resumes Phase 1 trial of PG-11047 - 05/14 - 09:17 PM ET

Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 - 05/14 - 09:16 PM ET

Progen Presents New Data On Patented PG500 Series Of Compounds At Annual AACR Meeting In San Diego - 04/14 - 02:42 AM ET

Progen Pharma Presents New Data On Patented PG500 Series Of Compounds At Annual AACR Meeting - Quick Facts - 04/14 - 02:16 AM ET

Progen Pharma. Presents New Data On Patented PG500 Series Of Compounds At Annual AACR Meeting - 04/14 - 01:55 AM ET

PG500 Series Presented at the AACR Annual Meeting in San Diego - 04/14 - 01:46 AM ET

Progen Pharma To Restructure Manufacturing And Drug Discovery Divisions - Update - 03/27 - 11:20 AM ET

PGLA: To Outsource Commercial Manufacture of PI-88; To Retain Facility - 03/27 - 10:06 AM ET

Progen To Outsource Commercial Manufacture Of PI-88 - Quick Facts - 03/27 - 09:21 AM ET

Progen Pharma Says It Restructures Manufacturing And Drug Discovery Divisions - 03/27 - 09:17 AM ET

Page 1 of 2     1  2      Previous  |  Next

<< Back to Stock Index